Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acer Therapeutics (ACER) shares

Learn how to easily invest in Acer Therapeutics shares.

Acer Therapeutics is a biotechnology business based in the US. Acer Therapeutics stocks (ACER.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.54 – a decrease of 4.07% over the previous week. Acer Therapeutics employs 30 staff and has a trailing 12-month revenue of around $900,000.

How to buy shares in Acer Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACER – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Acer Therapeutics stock price (NASDAQ:ACER)

Use our graph to track the performance of ACER stocks over time.

Acer Therapeutics shares at a glance

Information last updated 2022-01-16.
Latest market close$2.12
52-week range$1.68 - $5.39
50-day moving average $2.25
200-day moving average $2.56
Wall St. target price$11.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.24

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Acer Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Acer Therapeutics price performance over time

Historical closes compared with the close of $2.12 from 2022-01-21

1 week (2022-01-13) -5.78%
1 month (2021-12-20) N/A
3 months (2021-10-20) N/A
6 months (2021-07-23) -15.20%
1 year (2021-01-22) -42.23%
2 years (2020-01-24) -49.88%
3 years (2019-01-24) 23.9
5 years (2017-01-24) 112.00%

Acer Therapeutics financials

Revenue TTM $900,000
Gross profit TTM $0
Return on assets TTM -45.87%
Return on equity TTM -271.41%
Profit margin 0%
Book value $0.15
Market capitalisation $31.6 million

TTM: trailing 12 months

Acer Therapeutics share dividends

We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.

Have Acer Therapeutics's shares ever split?

Acer Therapeutics's shares were split on a 96:1000 basis on 20 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.

Acer Therapeutics share price volatility

Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $1.68 up to $5.39. A popular way to gauge a stock's volatility is its "beta".

ACER.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.1061. This would suggest that Acer Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Acer Therapeutics overview

Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts. .

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site